Centre for Biomedicine and Medical Technology Mannheim, Medical Faculty Mannheim, University Heidelberg, 68167 Mannheim, Germany.
Int J Cancer. 2013 Feb 1;132(3):E94-105. doi: 10.1002/ijc.27785. Epub 2012 Sep 7.
Cancer stem cells (CSCs) have been studied intensively in recent years due to their potential importance for understanding neoplastic disease and the design of antitumor therapies. A number of properties attributed to CSCs have been used to define the CSC population, the most important of which is the ability to initiate reproducibly the growth of tumors in vivo. Other assays such as spheroid formation, expression of particular markers and label retention are also used for defining CSCs, although the degree to which these assays invariably reflect the ability to form tumors in vivo remains to be carefully evaluated. Given the importance of correctly defining and isolating CSCs if valid conclusions about their characteristics are to be made, we used syngeneic animal models to compare these different assays. In standard spheroid assays, cell aggregation rather than spheroid growth from single cell suspensions ensued, but aggregation was circumvented by the inclusion of methylcellulose in the medium. Label-retaining subpopulations did not reliably exhibit an enhanced ability to form spheroids and were enriched for senescent cells. Spheroid-forming ability was found to correspond to expression of established CSC markers, although not invariably. Furthermore, spheroid-forming ability was not always reflected in tumor-initiating properties in vivo. Long-term culture of primary mammary tumor cells as adherent monolayers increased their tumor-initiating ability in vivo. This increase was attenuated when the cells were subsequently cultivated as spheroids. Together these data indicate that assays that are widely used to define CSC subpopulations do not invariably reflect tumor-initiating properties in vivo.
近年来,由于癌症干细胞(CSC)对于理解肿瘤疾病和设计抗肿瘤疗法具有潜在的重要性,因此对其进行了深入研究。已经使用了一些归因于 CSC 的特性来定义 CSC 群体,其中最重要的是能够在体内重复启动肿瘤生长的能力。其他测定方法,如球体形成、特定标志物的表达和标记保留,也用于定义 CSC,尽管这些测定方法在多大程度上始终反映体内形成肿瘤的能力仍需仔细评估。考虑到如果要对 CSC 的特征得出有效的结论,正确定义和分离 CSC 非常重要,因此我们使用同源动物模型来比较这些不同的测定方法。在标准球体测定中,细胞聚集而不是单细胞悬浮液中的球体生长,但是通过在培养基中加入甲基纤维素来避免聚集。保留标记的亚群并没有可靠地表现出形成球体的增强能力,而是富含衰老细胞。球体形成能力与已建立的 CSC 标志物的表达相关,但并非总是如此。此外,球体形成能力并不总是反映体内的肿瘤起始特性。作为贴壁单层培养的原代乳腺肿瘤细胞的长期培养增加了其体内的肿瘤起始能力。当随后将细胞培养成球体时,这种增加会减弱。这些数据表明,广泛用于定义 CSC 亚群的测定方法并不总是反映体内的肿瘤起始特性。